Endotoxin removal by the OXIRIS filter for cardiogenic shock requiring veno-arterial extra-corporeal life support: the ECMORIX randomized controlled trial
Authors' conclusion
In patients with cardiogenic shock supported by VA-ECMO and requiring renal replacement therapy, we could not evidence any reduction in LPS blood concentration in patients treated with treatment with OXIRIS filter in comparison to ST-150 filter.
Study context
- Population
- Patients with refractory cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and renal replacement therapy (RRT), cardiac ICU of Dijon University Hospitalall analysed
- Participants
- 40 patients
- Comparison
- OXIRIS filter vs ST-150 filter
- OXIRISn = 20
- ST-150n = 20reference
- Primary endpoint
- LPS mass
- Follow-up
- 24 h after the initiation of treatment
Methodological detailsopen-label, prospective, single-centre
- Open-label
- Prospective
- Single-centre
Primary result
As reported in the abstract
LPS plasma concentration (pmol/ml of esterified 3-OH fatty acids) · H24
P = 0.983
Secondary outcomes
LPS plasma concentration, all time points (linear mixed modelling) · H26, H48, H72 · not different
P = 0.882
H48 OXIRIS 576 [513;614] · ST-150 624 [503;724]
H72 OXIRIS 632 [513;660] · ST-150 586 [538;776]
- Lipopolysaccharide (LPS) plasma concentration, all time points (linear mixed modelling): values at H26
LPS activity, inflammation markers (IL-6, TNF-α, IL-10, MCP-1), SOFA scores, VIS scores
- No significant between-group differences
28-day mortality
- No significant between-group difference in 28-day mortality (OXIRIS vs ST-150)
- 13 (65%) vs 9 (45%) p = 0.21
Original publication
Endotoxin removal by the OXIRIS filter for cardiogenic shock requiring veno-arterial extra-corporeal life support: the ECMORIX randomized controlled trial. Ann Intensive Care. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →